The Middle Ages: Controversies in the Treatment of Adolescents and Young Adults With Leukemia

Over the past few decades, survival rates for pediatric patients with acute lymphocytic leukemia (ALL) have improved dramatically, with five-year survival rates now often exceeding 90 percent and 10-year survival rates exceeding 80 percent,...

Online Exclusives

FDA Approves Triplet Regimen for Multiple Myeloma

The U.S. Food and Drug Administration approved elotuzumab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory...

Regional Hospital Consortiums Hope to Compete for Clinical Trials

In a bid to attract research funding while reducing administrative costs, small hospitals across the U.S. are joining together to create clinical trial consortiums....

News

From the Blood Journals

WIB_icon

Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis

Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...

Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis

Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...

Multimedia

Pulling Back the Curtain: Vip Viprakasit, MD, DPhil

In more from our interview with Dr. Viprakasit, he speaks about the advantages of working in a limited-resource setting and the importance of international...

Let’s Get Cooking: Jonathan Hoggatt, PhD

In more from our interview with Dr. Hoggatt, he talks about the chocolate chip cookie experiment that started his obsession with cooking.

Pulling Back the Curtain: Richard W. Childs, MD

Hear more from our interview with Dr. Childs, where he talks about his inventive career in medicine and the best and worst parts of his...

Pulling Back the Curtain: Angela Thomas, OBE, PhD

Hear more from our interview with Dr. Thomas, where she talks about "converting" trainees to pediatric hematology and offers career advice for early-career hematologists.

On Location

Every Patient Tells a Story: Using Narrative Medicine to Cure Disease

As part of the Education Program at the 2018 ASH annual meeting, three physician-writers will...

Myeloma Therapy: From Diagnosis to Relapse

This year’s Education Program takes a new approach to disease-specific content: In two Special Education...

ASH-a-Palooza: Trainee Day. Reimagined.

The “Trainee Day” that attendees may know from past annual meetings has been reimagined as...

Serving the Next Generation of Hematologists: Interview with Reed E. Drews, MD

Reed E. Drews, MD, recipient of the 2018 Mentor Award in education, explains how he...

For the Love of the Lab: Interview with John E. Dick, PhD

John E. Dick, PhD, recipient of the 2018 Mentor Award in basic science, tells us...

From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal Residual Disease

During their presentations, MHM speakers will be asking the audience how they would respond to...

Latest Headlines

Advertisement

ASH Directions

Nancy Berliner Named Next Editor-in-Chief of Blood, and more

ASH Launches New Sickle Cell Disease Clinical Trials Network  ASH has announced the launch of a clinical trials network in sickle cell disease (SCD) to...

Announcing the 2018 Honorific and Mentor Award Recipients, and more

Announcing the 2018 Honorific and Mentor Award Recipients!  ASH will recognize these distinguished leaders in hematology through awards and special lectures at the 60th ASH...

Sign up for our
eNewsletter!

Lili Yang Wins $1.4 Million CIRM Quest Discovery Grant, and more

Remembering Thomas Michael Przybysz (1951-2018)  Thomas Michael Przybysz, MD, an oncologist, passed away on July 19, 2018, at the age of 66. After serving in the...

Jonas Sokolof Named Director of NYU Langone’s New Rehab Program for Cancer Survivors, and...

Jonas Sokolof Appointed Director of NYU Langone’s New Rehabilitation Program for Cancer Survivors  NYU Langone’s Rusk Rehabilitation has opened the Division of Oncological Rehabilitation, launching...

NIH Awards $24 Million to UT Health San Antonio, and more

Remembering Michael C. Lill (1959-2018)  Michael C. Lill, MD, passed away on June 19, 2018, after a long battle with cancer. Dr. Lill was born...

The Middle Ages: Controversies in the Treatment of Adolescents and Young Adults With Leukemia

Over the past few decades, survival rates for pediatric patients with acute lymphocytic leukemia (ALL) have improved dramatically, with five-year survival rates now often...

Who Pays What, and Why?

From R&D to PBMs, a look at the U.S. approach to drug pricing  When it comes to setting drug prices, the U.S. is singular in...

Rethinking Burnout

Will solving physician burnout require sweeping changes to the U.S. health-care system?  About 15 years ago, during the first year of his fellowship, Tait Shanafelt,...